Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in the U.S.: $3,285M in FY2025, down 18.9% from a year earlier.
Latest, FY2025
3,285
Period ended Dec 31, 2025
Change on a year earlier
-18.9%
4,052 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Entresto | Cardiovascular, renal and metabolic | Chronic heart failure, hypertension | 3 285 | -19 | 4 463 | 18 | 16 | 7 748 | -1 | -2”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in the U.S. ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,285 | -18.9% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 4,052 | +32.1% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 3,067 | +30.3% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 2,354 | +37.5% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2021 | Dec 31, 2021 | 1,712 | +34.1% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2020 | Dec 31, 2020 | 1,277 | +38.1% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 925 | +66.4% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2018 | Dec 31, 2018 | 556 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Cite this data
StockData. (2026). Novartis Net Sales in the U.S. ($M), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-entresto-us-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.